| MeSH term | MeSH ID | Detail |
|---|---|---|
| Parotid Diseases | D010305 | 1 associated lipids |
| Achlorhydria | D000126 | 1 associated lipids |
| Eye Infections | D015817 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Granuloma, Plasma Cell | D006104 | 1 associated lipids |
| Encephalomyelitis, Acute Disseminated | D004673 | 1 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Parotid Neoplasms | D010307 | 2 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Paul P et al. | Capillary electrophoresis with capacitively coupled contactless conductivity detection method development and validation for the determination of azithromycin, clarithromycin, and clindamycin. | 2017 | J Sep Sci | pmid:28683179 |
| Malfertheiner P et al. | Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. | 2017 | Gut | pmid:27707777 |
| Morimoto K et al. | A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. | 2017 | Ann Am Thorac Soc | pmid:27788025 |
| Aktas AH and Saridag AM | Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. | 2017 | J Chromatogr Sci | pmid:28449104 |
| Itskoviz D et al. | Smoking increases the likelihood of Helicobacter pylori treatment failure. | 2017 | Dig Liver Dis | pmid:28427781 |
| Wong AYS et al. | Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. | 2017 | Drug Saf | pmid:28397186 |
| Aziz DB et al. | Rifabutin Is Active against Mycobacterium abscessus Complex. | 2017 | Antimicrob. Agents Chemother. | pmid:28396540 |
| Maruyama M et al. | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Eradication: A Randomized Controlled Trial. | 2017 | Can J Gastroenterol Hepatol | pmid:28349044 |
| Brouqui P et al. | Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). | 2017 | Int. J. Antimicrob. Agents | pmid:28336312 |
| Yoon HY et al. | Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. | 2017 | Int. J. Tuberc. Lung Dis. | pmid:28826448 |
| Costa S et al. | Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. | 2017 | Eur J Gastroenterol Hepatol | pmid:28877088 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Santos RP et al. | induced rash and mucositis: a recently described entity. | 2017 | BMJ Case Rep | pmid:28830900 |
| Kwon S et al. | [The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in Eradication]. | 2017 | Korean J Gastroenterol | pmid:28830132 |
| Nanishi E et al. | Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. | 2017 | J Am Heart Assoc | pmid:28684643 |
| Fremlin GA et al. | Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. | 2017 | Clin. Exp. Dermatol. | pmid:28691163 |
| Andere NMRB et al. | Clarithromycin as an Adjunct to One-Stage Full-Mouth Ultrasonic Periodontal Debridement in Generalized Aggressive Periodontitis: A Randomized Controlled Clinical Trial. | 2017 | J. Periodontol. | pmid:28671507 |
| Adachi T et al. | Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. | 2017 | Oncology | pmid:29258111 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Tan B et al. | Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. | 2017 | PLoS ONE | pmid:28407007 |
| Freyne B and Curtis N | Mycobacterium gordonae Skin Infection in an Immunocompetent Child. | 2017 | Pediatr. Infect. Dis. J. | pmid:28403059 |
| Bustamante-Rengifo JA et al. | Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. | 2017 | World J. Gastroenterol. | pmid:28373764 |
| Marin AC et al. | Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. | 2017 | Drugs | pmid:28361211 |
| Holmberg LA et al. | Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. | 2017 | Acta Haematol. | pmid:28355602 |
| Lapa GB et al. | Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin. | 2017 | J Enzyme Inhib Med Chem | pmid:28097898 |
| Chen PY et al. | Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074519 |
| Zamani M et al. | Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. | 2017 | Aliment. Pharmacol. Ther. | pmid:28074507 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |
| Fernández Martos R et al. | Acute psychotic episode secondary to Helicobacter pylori eradication treatment. | 2017 | Rev Esp Enferm Dig | pmid:28071063 |
| Ko J et al. | Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review. | 2017 | Medicine (Baltimore) | pmid:29390522 |
| Muñoz-Egea MC et al. | Effect of Antibiotics and Antibiofilm Agents in the Ultrastructure and Development of Biofilms Developed by Nonpigmented Rapidly Growing Mycobacteria. | 2016 | Microb. Drug Resist. | pmid:26208145 |
| Salimi A et al. | Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. | 2016 | Xenobiotica | pmid:26068526 |
| Liou JM et al. | Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | 2016 | Lancet | pmid:27769562 |
| Campillo A et al. | [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. | 2016 | Gastroenterol Hepatol | pmid:27084668 |
| Chauffour A et al. | Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. | 2016 | PLoS Negl Trop Dis | pmid:27755552 |
| Morimoto K et al. | Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. | 2016 | Ann Am Thorac Soc | pmid:27513168 |
| Okano Y et al. | Miliary pulmonary nodules due to Mycobacterium xenopi in a steroid-induced immunocompromised patient successfully treated with chemotherapy: a case report. | 2016 | BMC Pulm Med | pmid:27287608 |
| Steurer J | [Months of antibiotic therapy in persistent symptoms of Lyme disease without effect]. | 2016 | Praxis (Bern 1994) | pmid:27269781 |
| Parize P et al. | Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. | 2016 | J Eur Acad Dermatol Venereol | pmid:25677464 |
| Huynh VA et al. | [Fixed drug eruption to clarithromycin: The importance of challenge tests in diagnosis]. | 2016 | Ann Dermatol Venereol | pmid:27080820 |
| EmiralioÄŸlu N et al. | Pulmonary Mycobacterium abscessus Infection in a Patient with Triple A Syndrome. | 2016 | J. Trop. Pediatr. | pmid:27080471 |
| Graham DY and Dore MP | Helicobacter pylori therapy: a paradigm shift. | 2016 | Expert Rev Anti Infect Ther | pmid:27077447 |
| Song ZQ et al. | Hybrid Therapy Regimen for Helicobacter Pylori Eradication. | 2016 | Chin. Med. J. | pmid:27064046 |
| Chua CS et al. | The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. | 2016 | Int J Food Sci Nutr | pmid:26883189 |
| Meng X et al. | [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province]. | 2016 | Zhonghua Yi Xue Za Zhi | pmid:26879786 |
| Bakshi SS | Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion. | 2016 | J Laryngol Otol | pmid:26878377 |
| Thung I et al. | Review article: the global emergence of Helicobacter pylori antibiotic resistance. | 2016 | Aliment. Pharmacol. Ther. | pmid:26694080 |
| Kamiya K et al. | Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. | 2016 | J. Dermatol. | pmid:26508502 |
| Lee J et al. | A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. | 2016 | J. Matern. Fetal. Neonatal. Med. | pmid:26373262 |
| Tsujimae M et al. | A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. | 2016 | Digestion | pmid:28030862 |